Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.21.1
License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended
Sep. 30, 2015
May 11, 2015
Jun. 30, 2019
May 31, 2016
Mar. 31, 2015
Mar. 31, 2021
Mar. 31, 2020
Commercial Sales In Specified Territories [Member] | PD-L1 [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments           $ 21,500,000  
Neupharma [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment of upfront licensing fees         $ 1,000,000.0    
Neupharma [Member] | Additional Sales Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments           40,000,000.0  
Neupharma [Member] | Clinical and Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments           40,000,000.0  
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments           22,500,000  
Dana-Farber [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Stock Issued During Period, Shares, Issued for Services 136,830 500,000          
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   5.00%          
Cash In Exchange For Common Stock   $ 10,000,000          
Payment For Non refundable Milestone payments             $ 925,000
Maintenance fee           50,000  
Stock Issued During Period, Value, Issued for Services $ 600,000 $ 32,500          
Shares Issued, Price Per Share   $ 0.065          
Dana-Farber [Member] | First Commercial Sale Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments           21,500,000  
Dana-Farber [Member] | Additional Sales Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments           60,000,000.0  
Jubilant Biosys Ltd [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment of upfront licensing fees       $ 2,000,000.0      
Revenue recognition milestone revenue recognized           $ 23,000 18,000
Proceeds from upfront fees       $ 1,000,000.0      
Research and development cost           50.00%  
Jubilant Biosys Ltd [Member] | Clinical and Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments           $ 89,000,000.0  
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments           59,500,000  
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments           61,700,000  
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments           89,000,000.0  
Maximum potential milestone payments           89,000,000.0  
Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestones [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments           87,200,000  
Adimab LLC [Member] | Clinical and Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments           7,100,000  
Adimab LLC [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments           4,800,000  
Collaboration Agreement With TGTX [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone revenue recognized           45,000 $ 954,000
Proceeds from upfront fees     $ 1,000,000.0   $ 500,000    
Collaboration Agreement With TGTX [Member] | First Commercial Sale Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments           14,500,000  
Collaboration Agreement With TGTX [Member] | First Commercial Sale Milestone [Member] | PD-L1 [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments           27,600,000  
Collaboration Agreement With TGTX [Member] | Clinical and Development Milestone [Member] | PD-L1 [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments           7,000,000.0  
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member] | PD-L1 [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments           19,200,000  
Collaboration Agreement With TGTX [Member] | Clinical Development and Regulatory Milestones [Member] | PD-L1 [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments           8,400,000  
Sublicense Agreement with TGTX [Member] | Clinical and Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments           $ 25,500,000